FDA Approval Update for TREXALL (Methotrexate Sodium) by Barr
The FDA has granted an Abbreviated New Drug Application (ANDA) approval for TREXALL, a methotrexate sodium product by Barr.
Published: July 20, 2026
Updated: July 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy
Company: Barr
Asset: TREXALL
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Barr
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Barr's TREXALL enhances its competitive positioning in the oncology market, particularly within the generic segment. This move could lead to increased market share and influence pricing strategies for methotrexate products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry and sales performance of TREXALL, as well as potential responses from competitors.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.